Hastrich D J, Dunn J M, Newcomb P, Hall P, Rooney N, Nicholson S, Farndon J R
Department of Surgery, Bristol Royal Infirmary.
J Clin Pathol. 1993 Feb;46(2):166-8. doi: 10.1136/jcp.46.2.166.
Epidermal growth factor receptor (EGFR) is a sensitive prognostic indicator in women with breast cancer. A new technique for the detection of EGFR on breast cancer imprints is described and evaluated in relation to immunohistochemistry on frozen sections. The standard streptavidin-biotin method using the R1 antibody on frozen sections was modified for use on tumour imprints. In the first group (group 1 imprints) 43 tumours were assessed by frozen section and imprint staining. The group 1 imprint method had a sensitivity of 50% and a specificity of 89% compared with the frozen sections. Further modifications were made for the following 32 tumours (group 2) and this method had a much improved sensitivity of 94% while specificity was preserved. This method is simple and could be performed in any hospital histopathology department.
表皮生长因子受体（EGFR）是乳腺癌女性患者的一个敏感预后指标。本文描述并评估了一种检测乳腺癌印片上EGFR的新技术，并将其与冷冻切片上的免疫组织化学方法进行了比较。使用R1抗体的标准链霉亲和素-生物素方法在冷冻切片上进行了改进，以用于肿瘤印片。在第一组（第1组印片）中，通过冷冻切片和印片染色对43个肿瘤进行了评估。与冷冻切片相比，第1组印片方法的敏感性为50%，特异性为89%。对接下来的32个肿瘤（第2组）进行了进一步改进，该方法的敏感性大幅提高至94%，同时保持了特异性。该方法简单，可在任何医院组织病理学科室进行。
